摘要
Stem cells may be the future of therapeutics for stroke due to their regenerative and immunomodulatory capabilities.Major barriers faced when employing stem cells,however,include faulty migration,low cell survival,and diminished proliferation.M ultilineage-differentiating stress ensuring (Muse) cells,a subset of mesenchymal stem cells,overcome these barriers.Muse cells aid in neuroregeneration,have immense regenerative potential,and are pluripotent,non-tumorigenic,and immunomodulatory.In stroke specifically,these cells may restore an a nti-inflammatory environment,regenerate damaged neurons,and integrate into the neuronal architecture.In fact,Muse cells may be aptly designed to ameliorate neurovascular unit damage following stroke and observed in other neuroinflammatory disorders.
基金
CVB was funded by the National Institutes of Health NIH R01NS090962,NIH R01NS102395,NIH R21 NS1095 75
CVB was funded and received royalties and stock options from Astellas,Asterias,Sanbio,Athersys,KMPHC
International Stem Cell Corporation and has also received consultant compensation from Chiesi Farmaceutici。
